sarpogrelate has been researched along with Cerebral Infarction in 4 studies
sarpogrelate: structure given in first source
Cerebral Infarction: The formation of an area of NECROSIS in the CEREBRUM caused by an insufficiency of arterial or venous blood flow. Infarcts of the cerebrum are generally classified by hemisphere (i.e., left vs. right), lobe (e.g., frontal lobe infarction), arterial distribution (e.g., INFARCTION, ANTERIOR CEREBRAL ARTERY), and etiology (e.g., embolic infarction).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The results of the Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS), a randomized double-blind study of sarpogrelate (selective 5-HT(2A) receptor antagonist) versus aspirin in 1510 Japanese patients, have been reported." | 9.14 | Sarpogrelate versus aspirin in secondary prevention of cerebral infarction: differential efficacy in diabetes? Subgroup analysis from S-ACCESS. ( Nishimaru, K; Shinohara, Y, 2009) |
| "In total, 1510 patients with recent cerebral infarction (1 week to 6 months after onset) were randomly assigned to receive either sarpogrelate (100 mg TID) or aspirin (81 mg/d)." | 9.13 | Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A randomized, double-blind, aspirin-controlled trial. ( Fukuuchi, Y; Gotoh, F; Handa, S; Hayashi, K; Hirai, S; Kobayashi, S; Kondo, K; Nishimaru, K; Otomo, E; Sawada, T; Shinohara, Y; Terashi, A; Tohgi, H; Uchiyama, S; Yamaguchi, T, 2008) |
| "Japanese guidelines recommend aspirin 160-300 mg/day, starting within 48 h, for patients with acute cerebral infarction." | 7.80 | Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014) |
| "The results of the Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS), a randomized double-blind study of sarpogrelate (selective 5-HT(2A) receptor antagonist) versus aspirin in 1510 Japanese patients, have been reported." | 5.14 | Sarpogrelate versus aspirin in secondary prevention of cerebral infarction: differential efficacy in diabetes? Subgroup analysis from S-ACCESS. ( Nishimaru, K; Shinohara, Y, 2009) |
| "In total, 1510 patients with recent cerebral infarction (1 week to 6 months after onset) were randomly assigned to receive either sarpogrelate (100 mg TID) or aspirin (81 mg/d)." | 5.13 | Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A randomized, double-blind, aspirin-controlled trial. ( Fukuuchi, Y; Gotoh, F; Handa, S; Hayashi, K; Hirai, S; Kobayashi, S; Kondo, K; Nishimaru, K; Otomo, E; Sawada, T; Shinohara, Y; Terashi, A; Tohgi, H; Uchiyama, S; Yamaguchi, T, 2008) |
| "Japanese guidelines recommend aspirin 160-300 mg/day, starting within 48 h, for patients with acute cerebral infarction." | 3.80 | Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shaikh, Q | 1 |
| Kamal, AK | 1 |
| Takahashi, S | 1 |
| Mizuno, O | 1 |
| Sakaguchi, T | 1 |
| Yamada, T | 1 |
| Inuyama, L | 1 |
| Shinohara, Y | 2 |
| Nishimaru, K | 2 |
| Sawada, T | 1 |
| Terashi, A | 1 |
| Handa, S | 1 |
| Hirai, S | 1 |
| Hayashi, K | 1 |
| Tohgi, H | 1 |
| Fukuuchi, Y | 1 |
| Uchiyama, S | 1 |
| Yamaguchi, T | 1 |
| Kobayashi, S | 1 |
| Kondo, K | 1 |
| Otomo, E | 1 |
| Gotoh, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A Randomized, Double-Blind, Aspirin-Controlled Trial[NCT00129805] | Phase 3 | 1,510 participants (Actual) | Interventional | 2001-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for sarpogrelate and Cerebral Infarction
| Article | Year |
|---|---|
Sarpogrelate versus aspirin in secondary prevention of cerebral infarction: differential efficacy in diabetes? Subgroup analysis from S-ACCESS.
Topics: Aged; Aspirin; Cerebral Infarction; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-U | 2009 |
Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A randomized, double-blind, aspirin-controlled trial.
Topics: Aged; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Double-Blind Method; Female; Humans; Incide | 2008 |
2 other studies available for sarpogrelate and Cerebral Infarction
| Article | Year |
|---|---|
Sarpogrelate- another new antiplatelet agent?
Topics: Aspirin; Cerebral Infarction; China; Female; Humans; Japan; Male; Platelet Aggregation Inhibitors; R | 2012 |
Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Cilostazol; Dipyridamole | 2014 |